Search - tctmd.com

Displaying 1 - 20 of 1847

Sort: Relevancy | Date

Presentation THT 2026

Effect of RV Function on Prognosis in HF and Valvular Heart Disease

Presenter: Kashish Goel

March 04, 2026

Presentation THT 2026

RV Response in Valvular Heart Disease

Presenter: Michael I. Brener

March 04, 2026

Presentation THT 2026

Real-World Utilization Patterns of Disease-Modifying Therapies in Transthyretin Amyloidosis: An EPIC Cosmos database study

Presenter: Arvind Bhimaraj

March 03, 2026

Presentation THT 2026

Debate: A Patient With MR Not Improving With GDMT: Go to VAD

Presenter: Jaya Batra

March 03, 2026

Presentation THT 2026

Debate: A Patient With MR Not Improving With GDMT: Try mTEER

Presenter: Karl-Philipp Rommel

March 03, 2026

Presentation THT 2026

Cardiomechanics Before and After mTEER: Insights From Pressure-Volume Analysis

Presenter: Nicolas M. Van Mieghem

March 03, 2026

Presentation THT 2026

Exercise-Induced MR: Implications for Diagnosis and Treatment

Presenter: Nikhil Narang

March 03, 2026

Presentation THT 2026

Medical Therapy for TR

Presenter: Sean P. Pinney

March 03, 2026

Presentation THT 2026

Anatomic Considerations for T-TEER and TTVR

Presenter: Jörg Hausleiter

March 03, 2026

Presentation THT 2026

An Emerging Problem: TR in Advanced Heart Failure (LVAD, OHT) Patients

Presenter: Michael I. Brener

March 03, 2026

Presentation THT 2026

Jena-VAD Trial Updates and Lessons Learned

Presenter: Gabriel Sayer

March 03, 2026

Presentation THT 2026

Case Presentation of LVAD-AR JenaValve Implantation (Prerecorded Live Case)

Presenter: Torsten P. Vahl

March 03, 2026

Presentation THT 2026

Characteristics associated with disease progression in patients with transthyretin amyloid cardiomyopathy treated with tafamidis

Presenter: Hanna Gaggin

March 03, 2026

Presentation THT 2026

Pulmonary Artery Denervation (PADN) Treatment in Patients with Pulmonary Hypertension Due to Left Heart Disease: Initial Results of the PreVail-PH2 Early Feasibility Study

Presenter: Ryan J. Tedford

March 03, 2026

Presentation THT 2026

Treating Danon Disease with Gene Therapy: Lessons Learned and Prospects for the Future

Presenter: Eric D. Adler

March 02, 2026

Presentation THT Abstracts 2026

SGLT2 Inhibitor Outcomes In Adult Congenital Heart Disease: A Retrospective Cohort Study

Presenter: Shaival Sharma

March 02, 2026

Presentation THT Abstracts 2026

Real-World Association of SGLT2 Inhibitors With Survival and Arrhythmic Risk in Advanced Cardio-Renal Disease

Presenter: Mazen Ahmed

March 02, 2026

Presentation THT 2026

AHF is an Opportunity To Improve CV Care — Arrhythmias, Ischemia, Valvular Heart Disease

Presenter: Marat Fudim

March 02, 2026

Presentation THT 2026

Management of Acute Decompensated Valvular Heart Disease

Presenter: Jörg Hausleiter

March 02, 2026

Presentation TCT 2025

Literature Update & Evidence Gaps - AR MR

Presenter: Syed Zaid

October 28, 2025

Advertisement

Effect of RV Function on Prognosis in HF and Valvular Heart Disease

RV Response in Valvular Heart Disease

Real-World Utilization Patterns of Disease-Modifying Therapies in Transthyretin Amyloidosis: An EPIC Cosmos database study

Debate: A Patient With MR Not Improving With GDMT: Go to VAD

Debate: A Patient With MR Not Improving With GDMT: Try mTEER

Cardiomechanics Before and After mTEER: Insights From Pressure-Volume Analysis

Exercise-Induced MR: Implications for Diagnosis and Treatment

Medical Therapy for TR

Anatomic Considerations for T-TEER and TTVR

An Emerging Problem: TR in Advanced Heart Failure (LVAD, OHT) Patients

Jena-VAD Trial Updates and Lessons Learned

Case Presentation of LVAD-AR JenaValve Implantation (Prerecorded Live Case)

Characteristics associated with disease progression in patients with transthyretin amyloid cardiomyopathy treated with tafamidis

Pulmonary Artery Denervation (PADN) Treatment in Patients with Pulmonary Hypertension Due to Left Heart Disease: Initial Results of the PreVail-PH2 Early Feasibility Study

Treating Danon Disease with Gene Therapy: Lessons Learned and Prospects for the Future

SGLT2 Inhibitor Outcomes In Adult Congenital Heart Disease: A Retrospective Cohort Study

Real-World Association of SGLT2 Inhibitors With Survival and Arrhythmic Risk in Advanced Cardio-Renal Disease

AHF is an Opportunity To Improve CV Care — Arrhythmias, Ischemia, Valvular Heart Disease

Management of Acute Decompensated Valvular Heart Disease

Literature Update & Evidence Gaps - AR MR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content